Filing Flows › Pharma-Bio Serv (PBSV) › Q3 FY26
Pharma-Bio Serv (PBSV) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Sep 14, 2026
Pharma-Bio Serv (PBSV) reported revenue of $2.3M for the third quarter fiscal 2026 (Q3 FY26), +19% from a year earlier and -14% from the quarter before. Operating margin was -3.1%, net loss $14K (0.6% of revenue).
Pharma-Bio Serv, Q3 FY26: revenue $2.3M (+19% year over year), operating margin -3.1%, net loss $14K, operating cash flow $61K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | -14% | +19% |
| Operating profit | −$72K | -150% | — |
| Net earnings | −$14K | -106% | — |
| Operating cash flow | $61K | — | -74% |
| Free cash flow | $60K | — | -75% |
What changed
Revenue was $2.3M in Q3 FY26, up 19% year over year and down 14% from the previous quarter.
Gross margin was 29.6%, up 0.4 points from Q3 FY25. Operating costs exceeded revenue by $72K, an operating margin of -3.1%. Operating expenses fell 14% while revenue rose 19%. The quarter ended with a net loss of $14K, after a profit of $233K the previous quarter. Non-operating items added $61K, -547% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $61K (down 74% year over year). Non-cash charges added back $14K of depreciation and amortization and $9K of share-based compensation. Working capital and other items added $53K. Capital expenditures of $1K left free cash flow of $60K.
Questions
What was Pharma-Bio Serv's revenue in the third quarter fiscal 2026?
Pharma-Bio Serv (PBSV) reported revenue of $2.3M for the third quarter fiscal 2026 (Q3 FY26), +19% from a year earlier and -14% from the quarter before.
Was Pharma-Bio Serv profitable in the third quarter fiscal 2026?
Operating loss was $72K (-3.1% of revenue) and net loss $14K.
Source: Pharma-Bio Serv 10-Q on SEC EDGAR.